Table 5.
Key findings of primary studies.
| Author | Pain Results | Effects on Other Variables | Desertion |
|---|---|---|---|
| Rowe E et al., 2004 [21] | There was a statistically significant decrease in the intervention group, from 21.7/50 to 14.7/50 at 3 months in VAS; p < 0.05). There were no improvements in the placebo group, (p > 0.05). |
There were no statistically significative improvements of urinary symptoms in the intervention group. There were no improvements in the control. |
There were 4 dropouts; 1 in the intervention group, and 3 in the placebo group. |
| Paick J-S et al., 2006 [20] | There was a statiscally significant improvement in NIH-CPSI score of the group with electromagnetism (p < 0.041). Intervention group had statistically significant improvements compared to the pharmacological group (p = 0.007). |
PVR values and peak flow did not change after treatment. There were improvements in QOL in both groups, in the intervention group from 9.5 to 6.5 (p = 0.005), and in the case of the control group from 8 to 6 (p = 0.003). I-PSS obtained a better result in elegtromagnetism group with electromagnetism (p = 0.002) than in the pharmacological group (p = 0.55) |
- |
| Kessler TM et al., 2014 [17] | There was a decrease in NIH-CPSI scale in the intervention group (p = 0.7) and in the control group (p = 0.24). | Regarding quality of life, there were statistically significant differences between both groups (p = 0.015) Both groups had improvements in urinary symptons, being higher in intervention group, although they were not statistically significant (p > 0.05). There were no differences in the rest of the variables. |
There was 1 dropout. |
| Brown CS et al., 2002 [19] | The MPQ score showed great improvements in the intervention group patients, but these were not statiscally significant. PPI was reduced, but this was not statistically significant (p > 0.05). The PRI-T score improved in the intervention group (p > 0.08). The PDI score improved significantly in the intervention group compared to 4% of placebo group (p < 0.02). |
In the CGI-S score, symptoms improved significant in 28% (p < 0.007) compared to the group placebo that improved by 10% (p < 0.02). | The study was divided into two parts, one part that lasted 2 weeks with 1 dropout; and another lasted 4 weeks, and there were 13 dropouts. |
| He W et al., 2020 [18] | There was a statistically significant decrease in NIH-CPSI scale (p < 0.05). | Regarding micturition symptoms, the control group improved from the initial, being statistically significant (p < 0.05); however, for pain, the intervention group had statistically significant improvements compared to pretreatment and the control group. In QoL, in both groups there were statistically significant improvements. |
There was not any desertion. |
VAS: visual analogic scale. NIH-CPSI: National Institute of Health Porstatitis Syndrome Index. QOL: quality of life. IP-SS: International Prostate Symptom Score. PVR: post void residual. RPM: residuo post miccional. PSA: antígeno prostático específico. PPI: present pain intensity. PRI-T: quality of pain. PDI: pain disability index. CGI: clinical global impressions scale.